Lance R. McMahon, Ph.D. - US grants

Affiliations: 
Pharmacology University of Texas Health Science Center - San Antonio 
Area:
Behavioral pharmacology

We are testing a new system for linking grants to scientists.

The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.

Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.

High-probability grants

According to our matching algorithm, Lance R. McMahon is the likely recipient of the following grants.
Years Recipients Code Title / Keywords Matching
score
1998 — 1999 Mcmahon, Lance R
F32Activity Code Description:
To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.

Cocaine Behaviors--Role of 5ht4 and 5ht6 Receptors

@ University of Texas Medical Br Galveston

0.946
2003 — 2005 Mcmahon, Lance R
R21Activity Code Description:
To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)

Drug Discrimination and Thc Withdrawal in Monkeys

@ University of Texas Hlth Sci Ctr San Ant

0.979
2004 — 2013 Mcmahon, Lance R
P51Activity Code Description:
To support centers which include a multidisciplinary and multi-categorical core research program using primate animals and to maintain a large and varied primate colony which is available to affiliated, collaborative, and visiting investigators for basic and applied biomedical research and training.
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

Treatment of Cannabinoid Withdrawal in Rhesus Monkeys

@ University of Texas Hlth Sci Ctr San Ant

0.99
2009 — 2018 Mcmahon, Lance R
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

Nicotine Dependence: Neuropharmacology in Monkeys

@ University of Texas Hlth Science Center

0.99
2009 — 2010 Mcmahon, Lance R
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

Pharmacotherapy of Cannabinoid Withdrawal: Pre-Clinical Studies

@ University of Texas Hlth Science Center

0.99
2019 — 2021 Mccurdy, Christopher R (co-PI) [⬀]
Mcmahon, Lance R
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

Kratom Alkaloids: in Vitro and in Vivo Pharmacological Mechanisms

@ University of Florida

0.964
2019 — 2021 Mccurdy, Christopher R. (co-PI) [⬀]
Mcmahon, Lance R
UG3Activity Code Description:
As part of a bi-phasic approach to funding exploratory and/or developmental research, the UG3 provides support for the first phase of the award. This activity code is used in lieu of the UH2 activity code when larger budgets and/or project periods are required to establish feasibility for the project.
UH3Activity Code Description:
The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

Opioid Use Disorders: Uf Pharmacy Medications Discovery and Development

@ University of Florida

0.964